CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis

CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis

Bibliographic Details
Main Authors:	Gelfand, JM, Abboud, H, Irani, SR, Nakajima, H, Piquet, A, Pittock, SJ, Yeh, EA, Overell, J, Rajan, S, El-Khairi, M, Lee, S-T
Format:	Conference item
Language:	English
Published:	Wiley 2022

Similar Items

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
by: Lee, S, et al.
Published: (2024)

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
by: Soon-Tae Lee, et al.
Published: (2024-08-01)

CSF Findings in Chinese Patients with NMDAR, LGI1 and GABABR Antibody-Associated Encephalitis
by: Qiao S, et al.
Published: (2024-03-01)

Comprehensive B-Cell Immune Repertoire Analysis of Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis
by: Jingjing Feng, et al.
Published: (2021-10-01)

Seizures and risk of epilepsy in anti‐NMDAR, anti‐LGI1, and anti‐GABABR encephalitis
by: Chun‐Hong Shen, et al.
Published: (2020-08-01)

A rare case of anti-LGI1 limbic encephalitis with concomitant positive NMDAR antibodies
by: Tuo Ji, et al.
Published: (2020-09-01)

Relapses of Anti-NMDAR, Anti-GABABR and Anti-LGI1 Encephalitis: A Retrospective Cohort Study
by: Rui Zhong, et al.
Published: (2022-06-01)

CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study
by: Mette Scheller Nissen, et al.
Published: (2021-12-01)

Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?
by: Irani, SR, et al.
Published: (2011)

CSF Mitochondrial N-Formyl Methionine Peptide as Complementary Diagnostic Tool in Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis
by: Li C, et al.
Published: (2024-12-01)

Characterization of cardiac bradyarrhythmia associated with LGI1-IgG autoimmune encephalitis
by: Hannah H. Zhao-Fleming, et al.
Published: (2022-10-01)

Intrathecal B cell activation in LGI1-antibody encephalitis
by: Lehmann-Horn, K, et al.
Published: (2020)

Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis.
by: Tofaris, G, et al.
Published: (2012)

Improving clinical practice with an old friend from the neuroimmunology toolkit: acute corticosteroids in LGI1 antibody encephalitis
by: Irani, SR
Published: (2021)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
by: Jang, Y, et al.
Published: (2018)

Comparison of antibody assays in anti-NMDAR encephalitis
by: Gastaldi, M, et al.
Published: (2016)

Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis.
by: Irani, SR, et al.
Published: (2011)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
by: Yoonhyuk Jang, et al.
Published: (2018-09-01)

LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes
by: Binks, S, et al.
Published: (2017)

LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures
by: Aurangzeb, S, et al.
Published: (2017)

Clonal hematopoiesis in LGI1‐antibody encephalitis
by: Soo Jean Shin, et al.
Published: (2024-10-01)

Psychiatric Manifestation of Anti-LGI1 Encephalitis
by: Dominique Endres, et al.
Published: (2020-06-01)

Detection of NMDARs antibodies in encephalitis
by: Gastaldi, M, et al.
Published: (2017)

In vivo n-methyl-d-aspartate receptor (NMDAR) density as assessed using positron emission tomography during recovery from NMDAR-antibody encephalitis
by: Galovic, M, et al.
Published: (2022)

Magnetic resonance imaging characteristics of LGI1-antibody and CASPR2-antibody encephalitis
by: Kelly, MJ, et al.
Published: (2024)

Anti-NMDAR antibodies, the blood–brain barrier, and anti-NMDAR encephalitis
by: Xiarong Gong, et al.
Published: (2023-12-01)

Positive LGI1 Antibodies in CSF and Relapse Relate to Worse Outcome in Anti-LGI1 Encephalitis
by: Li-li Cui, et al.
Published: (2021-12-01)

LGI1 encephalitis: Autoimmune epilepsy or movement disorder
by: Sujit A Jagtap, et al.
Published: (2023-01-01)

A Case of LGI1 Encephalitis Presenting with NORSE
by: Gökberk Metin, et al.
Published: (2024-03-01)

Pilomotor Seizures in a Patient With LGI1 Encephalitis
by: Jinxia Yang, et al.
Published: (2020-02-01)

Clinical features of limbic encephalitis with LGI1 antibody
by: Wang ML, et al.
Published: (2017-06-01)

NMDAR-antibody encephalitis: psychopathology and immunobiology
by: Al-Diwani, A
Published: (2020)

Psychiatric manifestations of anti-NMDAR encephalitis
by: D. Martins, et al.
Published: (2021-04-01)

The movement disorder associated with NMDAR-antibody encephalitis: an expert-rater video study
by: Varley, JA, et al.
Published: (2016)

Novel qEEG Biomarker to Distinguish Anti-NMDAR Encephalitis From Other Types of Autoimmune Encephalitis
by: Tomotaka Mizoguchi, et al.
Published: (2022-02-01)

Pathognomonic seizures in limbic encephalitis associated with anti-LGI1 antibodies.
by: Sen, A, et al.
Published: (2014)

Antibody Properties Associate with Clinical Phenotype in LGI1 Encephalitis
by: Susann Ludewig, et al.
Published: (2023-01-01)

Anti-LGI1 encephalitis with initiating symptom of seizures in children
by: Yang Wang, et al.
Published: (2023-04-01)

Functional and Structural Brain Alterations in Encephalitis With LGI1 Antibodies
by: Jianping Qiao, et al.
Published: (2020-04-01)

Ongoing germinal centre reactions contribute to N-methyl-D-aspartate receptor (NMDAR) antibody production in nmdar-antibody encephalitis
by: Makuch, M, et al.
Published: (2018)